[go: up one dir, main page]

JP2002508975A - レトロウイルスエンベロープの融合原性を改良するためのプロリン豊富配列の使用 - Google Patents

レトロウイルスエンベロープの融合原性を改良するためのプロリン豊富配列の使用

Info

Publication number
JP2002508975A
JP2002508975A JP2000540262A JP2000540262A JP2002508975A JP 2002508975 A JP2002508975 A JP 2002508975A JP 2000540262 A JP2000540262 A JP 2000540262A JP 2000540262 A JP2000540262 A JP 2000540262A JP 2002508975 A JP2002508975 A JP 2002508975A
Authority
JP
Japan
Prior art keywords
envelope glycoprotein
mlv
proline
retroviral
retroviral envelope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000540262A
Other languages
English (en)
Japanese (ja)
Inventor
コッセ，フランソワ−ロワ
ラヴィレット，ディミトリ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Publication of JP2002508975A publication Critical patent/JP2002508975A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6045—RNA rev transcr viruses
    • C12N2810/6054—Retroviridae

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
JP2000540262A 1998-01-15 1999-01-07 レトロウイルスエンベロープの融合原性を改良するためのプロリン豊富配列の使用 Pending JP2002508975A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR98/00342 1998-01-15
FR9800342A FR2773561A1 (fr) 1998-01-15 1998-01-15 Utilisation d'une sequence riche en proline pour augmenter le caractere fusogenique d'enveloppes de retrovirus
PCT/FR1999/000016 WO1999036561A1 (fr) 1998-01-15 1999-01-07 Utilisation d'une sequence riche en proline pour augmenter le caractere fusogenique d'enveloppes de retrovirus

Publications (1)

Publication Number Publication Date
JP2002508975A true JP2002508975A (ja) 2002-03-26

Family

ID=9521783

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000540262A Pending JP2002508975A (ja) 1998-01-15 1999-01-07 レトロウイルスエンベロープの融合原性を改良するためのプロリン豊富配列の使用

Country Status (5)

Country Link
EP (1) EP1047791A1 (fr)
JP (1) JP2002508975A (fr)
CA (1) CA2317026A1 (fr)
FR (1) FR2773561A1 (fr)
WO (1) WO1999036561A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1115290T3 (da) 1998-10-01 2009-06-22 Univ Southern California Retroviralt gentilförselssystem og fremgangsmåder til anvendelse heraf
WO2000071578A2 (fr) * 1999-05-20 2000-11-30 Cnrs Centre National De La Recherche Scientifique Nouveaux polypeptides et leur utilisation pour le sauvetage de virus ou de glycoproteines virales a defaut de fusion
WO2007107156A2 (fr) * 2006-03-17 2007-09-27 Aarhus Universitet Enveloppes virales chimériques
EA201790824A3 (ru) 2008-09-26 2017-12-29 Токаджен Инк. Векторы для генной терапии и цитозиндезаминазы
US8829173B2 (en) 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
EP2632491A4 (fr) 2010-10-31 2014-10-01 Tocagen Inc Traitement et surveillance améliorés du cancer au moyen de vecteurs recombinants
CN104884627A (zh) 2012-10-25 2015-09-02 托卡根公司 具有小型启动子盒的逆转录病毒载体
US9642921B2 (en) 2012-12-20 2017-05-09 Tocagen Inc. Cancer combination therapy and recombinant vectors
CA2996797A1 (fr) 2015-09-04 2017-03-09 Tocagen Inc. Vecteurs de recombinaison comprenant un peptide 2a

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0746625B1 (fr) * 1992-11-09 2004-03-31 THE UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Particules vectorielles pouvant etre ciblees
FR2748747B1 (fr) * 1996-05-20 1998-08-07 Centre Nat Rech Scient Particules virales recombinantes comportant un peptide ayant des proprietes de masquage et de demasquage vis-a-vis d'un mecanisme biologique

Also Published As

Publication number Publication date
CA2317026A1 (fr) 1999-07-22
FR2773561A1 (fr) 1999-07-16
EP1047791A1 (fr) 2000-11-02
WO1999036561A1 (fr) 1999-07-22

Similar Documents

Publication Publication Date Title
Robison et al. The membrane-proximal stem region of vesicular stomatitis virus G protein confers efficient virus assembly
Gillet et al. Mechanisms of leukemogenesis induced by bovine leukemia virus: prospects for novel anti-retroviral therapies in human
Lavillette et al. Activation of membrane fusion by murine leukemia viruses is controlled in cis or in trans by interactions between the receptor-binding domain and a conserved disulfide loop of the carboxy terminus of the surface glycoprotein
Morikawa et al. Analyses of the requirements for the synthesis of virus-like particles by feline immunodeficiency virus gag using baculovirus vectors
US5554524A (en) More complex type retroviruses having mixed type LTR, and uses thereof
Kim et al. HTLV-1 and-2 envelope SU subdomains and critical determinants in receptor binding
JPH10506008A (ja) ＨＩＶ−１ Ｖｐｒ 融合分子に基づいたＨＩＶビリオン中へのタンパク質ターゲッティング
JP5060284B2 (ja) ウイルスタンパク質の免疫抑制作用のモデュレーションに関与するポリペプチド配列
CN112442514B (zh) 慢病毒包装载体系统、慢病毒及其构建方法、试剂盒
Zavorotinskaya et al. Suppression of a fusion defect by second site mutations in the ecotropic murine leukemia virus surface protein
JP2002508975A (ja) レトロウイルスエンベロープの融合原性を改良するためのプロリン豊富配列の使用
Morling et al. Masking of retroviral envelope functions by oligomerizing polypeptide adaptors
JP3954151B2 (ja) フォーミーウイルスエンベロープタンパク質の発現
EP0651806B1 (fr) Vaccins contre le virus de l'immunodeficience anti-feline (vif)
CA2282394C (fr) Vecteurs retroviraux, leur procede de production et leur utilisation pour le transfert genique dans des cellules positives cd-4
US6132731A (en) Murine leukemia virus vectors
Eksmond et al. Mutation of the putative immunosuppressive domain of the retroviral envelope glycoprotein compromises infectivity
Salamango et al. In vivo analysis of infectivity, fusogenicity, and incorporation of a mutagenic viral glycoprotein library reveals determinants for virus incorporation
Alfadhli et al. Second site reversion of HIV-1 envelope protein baseplate mutations maps to the matrix protein
Martinez et al. Mapping of receptor binding domains in the envelope protein of spleen necrosis virus
US20060067948A1 (en) Viral vectors
Burns et al. Mutations within a putative cysteine loop of the transmembrane protein of an attenuated immunodeficiency-inducing feline leukemia virus variant inhibit envelope protein processing
EP1183383B1 (fr) Vecteurs a encapsidation deficiente bases sur le siv
Modulates A Proline-Rich Motif Downstream of the
Mirsaliotis et al. Conformation-specific antibodies targeting the trimer-of-hairpins motif of the human T-cell leukemia virus type 1 transmembrane glycoprotein recognize the viral envelope but fail to neutralize viral entry